Cost and effectiveness of the California triple marker prenatal screening program

Genetics in Medicine

Volumn 1, Issue 5, 1999, Pages 199-206

  Cunningham, George C ^a   Tompkinson, D Gwynne ^a  

^a Genetic Disease Breach   (United States)

Author keywords

Birth defects; Cost benefit; Prenatal care; Prevention; Screening

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; ESTRIOL;

ARTICLE; BLOOD; COST BENEFIT ANALYSIS; DOWN SYNDROME; ECONOMICS; EVALUATION; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; KARYOTYPING; NEURAL TUBE DEFECT; PREGNANCY; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CALIFORNIA; CHORIONIC GONADOTROPIN; COST-BENEFIT ANALYSIS; DOWN SYNDROME; ESTRIOL; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HUMANS; KARYOTYPING; NEURAL TUBE DEFECTS; PREGNANCY; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 0033157130     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/00125817-199907000-00006     Document Type: Article

References (33)

1. Andrews LB, Fullarton IE, Holtzman NA, Motutsky AG. Assessing genetic risks: Implications for health and social policy, Washington, DC: National Academy Press, 1994.
2. Omenn GS. Genetics and public health. Am/Public Health 1996:86:1701-1704.
3. Khoury MI. From genes to public health: The applications ot genetic technology disease prevention. Am/Public Health 1996;86:1717-1722.
4. Brock DH, Bolton AE, Scrimgeour IB. Prenatal diagnosis of spina bifida and anencephaiy through maternal plasma-alpha-fetoprotein measurement. Lancet 1974;i:767.
5. Second Report of the LUC Collaborative Study on Alpha-fetoprotein in Relation to Neural Tube Defects. Ammotic Fluid Alpha-fetoprotein Measurement in Antenatal Diagnosis of Anencephaly and Open Spina Bifida in Early Pregnancy. Lancet 1979;ii:652.
6. Macri IN, Haddow IE, Weiss RR. Screening for neural tube detects in the united states. Am I Obstet Gynecol 1979; 133:119-123.
7. Consensus Meeting Special Report. Maternal serum alpha-fetoprotein screening for neural tube defects. Prenat Diagn 1985;5:77-83.
8. American Society of Human Genetics. Policy Statement for a Maternal Serum Alpha Fetoprotein Screening Program. ASHG, Derwood, Maryland, November 2, 1986.
9. Cuckle HS, Wald N, Thompson N. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age, and serum alpha-fetoprotein level. BA 1981;94:387-402.
10. Wald N, Cuckle HS, Densem W, Nanchahal K, Royston P, Whard T, Haddow IE, Knight GI, Palomaki GE, Canick IA. Maternal screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-887.
11. Estimating an individual's risk of having a fetus with open spina bifida and the value of repeat alpha-fetoprotein testing. Fourth report of the LUitcd Kingdom Collaborative Study on Alpha-Fetoprotein in Relation to Neural Tube Defects. Epidemiol Common Health 1982;36:87-95.
12. Glass N. Economic aspects of the prevention of Down's syndrome (Mongolism). In: Bailey NTJ, Thompson M, editors. Systems aspects of health planning. Amsterdam: North-Holland, 1975:725-732.
13. Hagard S, Carter F. Preventing the birth of infants with Down’s syndrome. A cost benefit analysis. BMJ 1976;27:753-756.
14. Mikkelsen M, Nielsen G. Cost benefit analysis ot prevention of Down’s syndrome. In: Boue A, editor. Les Colloques de l'lnstitut National de la Sante ct de la Recherche Medicale. Prenatal Diagnosis. Paris: INSERM, 1976:61:283-289.
15. Shackley P, McGuire A, Boyd PA, Dennis I, Fitchett M, Kay I, Roche M, Wood P. An economic appraisal of alternative pre-natal screening programmes for Down’s syndrome. Public Health Med 1993:15:1 75-184.
16. Tapin SH, Thompson RS, Conrad DA. Cost justification analysis of prenatal serum alpha fetoprotein screening. Med Care 1988:26:1185-1202.
17. Williamson R. Improved screening for fetal chromosome abnormalities. Iowa Med 1990;80:125-128.
18. Sheldon TA, Simpson J. Appraisal of a new scheme for prenatal screening for Down’s syndrome. BMJ 1991:302:1 133-1136.
19. Sadovnick AD, Baird PA. A cost benefit analysis of prenatal detection of Down syndrome and neural tube defects in older mothers. Am J Med Genet 1981;10:367-378.
20. Goldstein H, Philip J, Dupont A. One year of health and social services for children 3-7 years old with Down syndrome. Soc Psychiatry 1986:21:134-138.
21. Campbell TL. Maternal serum alpha feto-protein screening: Benefits, risks and costs. J Pam Pract 1987;25:461-467.
22. Layde PM, von Allmen SD, Oakley GP Ir. Maternal serum alpha-fetoprotein screening: a cost-benefit analysis. Am J Public Health 1979;69:566-573.
23. Gill M, Murday V, Slack J. An economic appraisal of screening for Down's syndrome in pregnancy using maternal age, and serum alpha fetoprotein concentration. Soc Sci Med 1987;24:725-731.
24. Edel CM, Edel M. Economic costs of aneuploidy: Some problems of measurement and conceptualization. In: Dellarco VL, Voylek PE, editors. Aneuploidy etiology and mechanisms. New York: Plenum Press, 1985;61-73.
25. Braddock D, Hemp R, Howes R. Direct costs of institutional care in the United States. Mental Retard 1986;24:9-17.
26. Ginsberg G. Costs of caring tor spina bifida and Down syndrome. Unpublished report. State of New York, Department of Health, 1987.
27. Seror V, Moatti IP, Muller F, Le Gales C, Boue A. Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood. Rev Epidemiologic Sante Pubhque 1993;41:3-15.
28. Seror V, Muller F, Moatti IP, Le Gales C, Boue A. Economic assessment of maternal serum screening for Down's syndrome using human chorionic gonadotropin. Prenat Diagn 1993;13:281-292.
29. Conley RW. Down syndrome: Economic burdens and benefits of prevention. In: Dellarco VL, Voylek PE, editors. Aneuploidy etiology and mechanisms. New York: Plenum Press, 1985:35-57.
30. Hook EB. Genetic counseling and prenatal cytogenetic services: Policy implications and detailed cost benefit analysis of program for the prevention of Down syndrome. In: Porter IH, Hook EB, eds. Birth defects institute, symposia, service and education in medical genetics. New York: Academic Press,1979:29-54.
31. Hook EB, Chambers GM. Estimated rates of Down syndrome in live births by one year maternal age intervals for mothers aged 20-49 in New York State study. Implications of the risk figures for genetic counseling and cost benefit analysis of prenatal diagnosis programs. Birth Defect Original Article Series, Vol XIII, No. 3A; 1977:123-141.
32. Waitzman NI, Romano PS, Scheffler RM. Estimates of the costs of birth defects. Inquiry 1994;33:188-205.
33. Bishop I, Huether CA, Tofts C, Lorcy F, Deddens J. Epidemiologic study of Down syndrome in a racially diverse California population. 1989-1994. Am J Epidemiol 1997;145:134-147.